8-K Announcements
6Material company update
Jun 10, 2026·SEC
Material company update
May 4, 2026·SEC
Material company update
Apr 23, 2026·SEC
Masimo faces a complex transition as it attempts to reconcile its high-margin clinical monitoring business with the lower-margin consumer audio segment, leading to significant earnings volatility and margin compression. While the company has successfully reduc...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth remains inconsistent, evidenced by a 27.10% year-over-year contraction and gross margins that have struggled to recover from a 40.7% low in 2024Q4.
Masimo develops and manufactures innovative noninvasive patient monitoring technologies and medical devices, positioning it as a leader in healthcare innovation.
Wall Street expects Masimo to deliver $1.41 per share for Q1 2026, representing a 3.68% growth compared to the previous year, indicating strong financial performance.
Masimo's acquisition by Danaher is seen as a bullish catalyst, with the deal set to close imminently and likely to drive investor interest and market outperformance.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 5, 2026 | $1.43+1.4% vs $1.41 | $400M+0.2% vs $399M |
Q1 2026 Feb 26, 2026 | $0.18-87.8% vs $1.48 | $413M+1.1% vs $408M |
Q4 2025 Nov 4, 2025 | $1.32+10.9% vs $1.19 | $372M-8.9% vs $408M |
Q3 2025 Aug 5, 2025 | $1.33+8.1% vs $1.23 | $371M+0.5% vs $369M |
Benchmark MASI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Masimo Corporation (MASI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $179.95 | $9.42B | -64.27 | -27.1% | -9.92% | -17.09% | — | |
| $136.49 | $9.45B | 39.22 | 30.73% | 12.29% | 26.69% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $163.32 | $4.08B | 5555.10 | -6.38% | 1.39% | 1.41% | — |
Masimo Corporation (MASI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Masimo Corporation (MASI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 10, 2026·SEC
May 4, 2026·SEC
Apr 23, 2026·SEC
Get notified when MASI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Masimo Corporation (MASI) stock FAQ — growth, dividends, profitability & financials explained
Masimo Corporation (MASI) reported $1.56B in revenue for fiscal year 2025. This represents a 91576% increase from $1.7M in 1998.
Masimo Corporation (MASI) saw revenue decline by 27.1% over the past year.
Yes, Masimo Corporation (MASI) is profitable, generating $76.3M in net income for fiscal year 2025 (-9.9% net margin).
Masimo Corporation (MASI) has a return on equity (ROE) of -17.1%. Negative ROE indicates the company is unprofitable.
Masimo Corporation (MASI) generated $208.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.